SCHEMBL12404499

CC(=O)NC1C(O)[C@H](O[C@@H]2OC(CO[C@]3(C(=O)O)C[C@@H](O)[C@@H](NC(C)=O)C([C@H](O)[C@H](O)CO)O3)[C@H](O)[C@H](O)C2O)[C@H](CO)O[C@H]1OC1[C@@H](OCC2O[C@@H](O[C@@H]3C(CO)O[C@@H](O[C@@H]4C(CO)O[C@@H](NC(=O)CBr)C(NC(C)=O)[C@H]4O)C(NC(C)=O)[C@H]3O)C(O)[C@@H](O[C@H]3OC(CO)[C@@H](O)C(O)C3O[C@@H]3OC(CO)[C@@H](O[C@@H]4OC(CO[C@]5(C(=O)O)C[C@@H](O)[C@@H](NC(C)=O)C([C@H](O)[C@H](O)CO)O5)[C@H](O)[C@H](O)C4O)[C@H](O)C3NC(C)=O)[C@@H]2O)OC(CO)[C@@H](O)[C@@H]1O

nearest known ligand 0.61

Predicted protein targets (top 6)

	gene	UniProt	supporting neighbours	confidence
▸	SIGLEC7	Q9Y286	6/20	0.61

▸	MAG	P20916	8/20	0.55

▸	SELP	P16109	2/20	0.50

▸	SELL	P14151	1/20	0.50

▸	SELE	P16581	2/20	0.46

▸	CD209	Q9NNX6	1/20	0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL14570812	0.97	SIGLEC7 (0.60)	SIGLEC7MAGSELPSELLSELE
SCHEMBL16350798	0.93	SIGLEC7 (0.60)	SIGLEC7MAGSELPSELLSELE
SCHEMBL14331790	0.93	SIGLEC7 (0.60)	SIGLEC7MAGSELPSELLSELE
SCHEMBL13004057	0.93	SIGLEC7 (0.60)	SIGLEC7MAGSELPSELLSELE
SCHEMBL2629581	0.93	SIGLEC7 (0.60)	SIGLEC7MAGSELPSELLSELE
SCHEMBL12197082	0.92	SIGLEC7 (0.61)	SIGLEC7MAGSELPSELLSELE
SCHEMBL30532209	0.92	SIGLEC7 (0.65)	SIGLEC7MAGSELPSELLSELE
SCHEMBL13004041	0.92	SIGLEC7 (0.65)	SIGLEC7MAGSELPSELLSELE
SCHEMBL14570809	0.91	SIGLEC7 (0.58)	SIGLEC7MAGSELPSELLSELE
SCHEMBL13004060	0.91	SIGLEC7 (0.63)	SIGLEC7MAGSELPSELLSELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-7985731-B2	Sugar chain added GLP-1 peptide	OTSUKA CHEMICAL HOLDINGS CO., LTD. (JP)	2011-07-26	—	—	US	disclosed
US-7851618-B2	Aminated complex-type sugar chain derivatives and process for the production thereof	OTSUKA CHEMICAL CO., LTD. (JP)	2010-12-14	—	—	US	disclosed
US-20090111739-A1	SUGAR CHAIN ADDED GLP-1 PEPTIDE	OTSUKA CHEMICAL CO., LTD. (JP)	2009-04-30	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20090111739-A1	SUGAR CHAIN ADDED GLP-1 PEPTIDE	GLP1R, IAPP, GIPR	SIGLEC7 308/4885MAG 1836/4885SELP 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.